Audited Standalone and Consolidated Financial Results for quarter and year ended March 31, 2026.
VALIANTLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.6 pts less than Nifty Microcap 250, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Valiant Laboratories reported strong revenue growth with standalone revenue of Rs 21,704 lakhs for FY26, up 63% from Rs 13,336 lakhs in FY25. The company turned profitable at standalone level with net profit of Rs 555 lakhs versus a loss of Rs 215 lakhs in the prior year. However, on a consolidated basis, the group posted a net loss of Rs 327 lakhs (vs loss of Rs 220 lakhs), indicating the subsidiary Valiant Advanced Sciences Private Limited is dragging overall profitability. Standalone EBITDA margin expanded significantly to 4.6% from 0.5% in FY25. Finance costs increased substantially at consolidated level (Rs 190 lakhs vs Rs 18 lakhs) due to higher borrowings. The statutory auditor issued an un-modified (clean) opinion on both standalone and consolidated financial statements.
Positive for standalone shareholders as the company returned to profitability with strong revenue growth, but consolidated shareholders face continued losses driven by the subsidiary, requiring monitoring of subsidiary performance and debt servicing costs.